Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 137

Sort by

Sort Order Select

Journal Articles

The Clinical Efficacy and Safety of Glofitamab in Chinese Relapsed or Refractory Large B-Cell Lymphoma

Yingyu Dong, Weili Zhao, Li Wang

Blood (2024) 144 (Supplement 1): 6522.

https://doi.org/10.1182/blood-2024-204848

Published: 2024

Journal Articles

A Phase 2 Multicenter Study of Pegaspargase in Combination with Gemcitabine, Etoposide, Mitoxantrone Hydrochloride Liposome, and Dexamethasone (P-GEMD) for Newly Diagnosed Early Non-Upper Aero-Digestive Tract or Advanced Stage Extranodal NK/T Cell Lymphoma

Jinhua Liang, Hao-Rui Shen, Hua Yin, Jiazhu Wu, Yue Li, Li Wang, Jianyong Li, Liang Wang, Xu Wei

Blood (2024) 144 (Supplement 1): 6396.

https://doi.org/10.1182/blood-2024-203071

Published: 2024

Journal Articles

Auto-HSCT Vs CAR-T Cell Therapy for Paients with Relapsed/Refractory DLBCL in Partial Remission with Deauville Score of 4 or 5 after Salvage Chemotherapy

Siyuan Chen, Li Wang, Pengpeng Xu, Shu Cheng, Wei Tang, Wen Wu, Mengmeng Ji, Zhong Zheng, Zixun Yan, Lingshuang Sheng, Yige Shen, Weili Zhao

Blood (2024) 144 (Supplement 1): 6553.

https://doi.org/10.1182/blood-2024-203842

Published: 2024

Journal Articles

A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma

Jinhua Liang, Li Wang, Haorui Shen, Hua Yin, Jiazhu Wu, Yue Li, Bihui Pan, Xinyu Zhang, Yilin Kong, Jianyong Li, Xu Wei

Blood (2024) 144 (Supplement 1): 1742.3.

https://doi.org/10.1182/blood-2024-207064

Published: 2024

Journal Articles

Guidance 05: A Prospective, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Genotype-Guided Targeted Agents in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (POLA-RCHP-X) Versus Pola-Rchp in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Shu Cheng, Li Wang, Pengpeng Xu, Muchen Zhang, Weili Zhao

Blood (2024) 144 (Supplement 1): 4502.3.

https://doi.org/10.1182/blood-2024-204749

Published: 2024

Journal Articles

Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

Xin Li, Jia Wei, Dong-feng Zeng, Shu-nan Qi, Bingzong Li, Wei Guo, Li Wang, Yajun Li, Xudong Zhang, Yong Yang, Shukai Qiao, Yan Zeng, Yunfei Song, Jing-wen Wang, Jian-min Ma, Liang Wang

Blood (2024) 144 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2024-206489

Published: 2024

Journal Articles

Serum Tsrna Can be Used As a Biomarker of the Activation States of T Cells for Early Detection of GvHD after Allogeneic Stem Cell Transplantation

Lin Xia, Wei Xu, Shuhan Tang, Han Yao, Lu Zhao, Yuqing Liu, Ting Chen, Jie Tang, Xiaoli Chen, Li Wang, Shijie Yang, Yimei Feng, Xi Zhang

Blood (2024) 144 (Supplement 1): 7107.

https://doi.org/10.1182/blood-2024-204395

Published: 2024

Journal Articles

Over-Expression of GATA3 in Large B-Cell Lymphoma Predicts Better Prognosis

Fan Zhang, Jiaying Liu, Yuting Dai, Di Fu, Yige Shen, Li Wang, Weili Zhao

Blood (2024) 144 (Supplement 1): 6272.

https://doi.org/10.1182/blood-2024-204855

Published: 2024

Journal Articles

Investigating Prognostic Value of Immunoglobulin Next-Generation Sequencing in B Cell Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Yi-Lun Zhang, Lingshuang Sheng, Rong Shen, Wen Wu, Xin Zheng, Li Wang, Shu Cheng, Peng-Peng Xu, Qi-Jie Jian, Bo Peng, Ke Zhang, Fei Pang, Kai Wang, Zi-Xun Yan, Wei-Li Zhao

Blood (2024) 144 (Supplement 1): 6208.

https://doi.org/10.1182/blood-2024-209889

Published: 2024

Journal Articles

Integration of Gene Mutations in Risk Prognostication for Watch-and-Wait Follicular Lymphoma Patients Initiating First-Line Treatment

Tianyuan Xu, Nan Wang, Rui Sun, Ruichi Li, Di Fu, Yan Zhao, Pengpeng Xu, Shu Cheng, Li Wang, Wei Tang, Zhong Zheng, Weili Zhao

Blood (2024) 144 (Supplement 1): 6200.

https://doi.org/10.1182/blood-2024-204775

Published: 2024

Journal Articles

R-Cmop and Pola-R-CMP Regimes As First-Line Treatment for Diffuse Large B-Cell Lymphoma with Cardiac Comorbidity

Jinhua Liang, Yue Li, Haorui Shen, Jiazhu Wu, Hua Yin, Li Wang, Xu Wei

Blood (2024) 144 (Supplement 1): 6532.

https://doi.org/10.1182/blood-2024-212300

Published: 2024

Journal Articles

Targeting YTHDC1 Inhibited the Progression of Mantle Cell Lymphoma By Inhibiting the Expression of MYC Gene through m6A Modification

Hui Zhou, Li Wang, Ruicheng Yang, Guifeng Lin, Hailin Zhang, Ting Niu

Blood (2024) 144 (Supplement 1): 5821.

https://doi.org/10.1182/blood-2024-207319

Published: 2024

Journal Articles

Practical Microenvironment Classification in Diffuse Large B-Cell Lymphoma Using Digital Pathology

Yuqing Wang, Shuo Wang, Hongmei Yi, Yue Wang, Haimin Xu, Shuang Tian, Yan Dong, Jing Zhao, Di Fu, Rongji Mu, Shuye Wang, Li Wang, Pengpeng Xu, Wei Li Zhao

Blood (2024) 144 (Supplement 1): 4974.

https://doi.org/10.1182/blood-2024-202864

Published: 2024

Journal Articles

The First-in-Class PTPN2/1 Inhibitor Abbv-CLS-484 Disrupts Mitochondrial Renewal and Blocks Tfrc-Mediated PINK1-Prkn-Dependent Mitophagy to Exert Anti-Tumor Activities in ALK-Positive Anaplastic Large Cell Lymphoma

Jinhua Liang, Weiting Wang, Ziwen Duan, Tong-Yao Xing, Hao-Rui Shen, Hua Yin, Li Wang, Jianyong Li, Xu Wei

Blood (2024) 144 (Supplement 1): 2742.

https://doi.org/10.1182/blood-2024-201488

Published: 2024

Journal Articles

Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort

Jinhua Liang, Yi-fan Wu, Jun-heng Liang, Yue Li, Xin-Yu Zhang, Hao-Rui Shen, Jiazhu Wu, Liu qing Zhu, Hua Yin, Li Wang, Jianyong Li, Xu Wei

Blood (2024) 144 (Supplement 1): 576.

https://doi.org/10.1182/blood-2024-194820

Published: 2024

Journal Articles

A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia

Blood (2024) 144 (Supplement 1): 378.

https://doi.org/10.1182/blood-2024-204984

Published: 2024

Journal Articles

Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma：a Phase 2 Multicenter Study

Jinhua Liang, Hao-Rui Shen, Hua Yin, Jiazhu Wu, Yue Li, Li Wang, Lintao Bi, Weiwei Qin, Jianyong Li, Xu Wei

Blood (2024) 144 (Supplement 1): 1725.

https://doi.org/10.1182/blood-2024-202967

Published: 2024

Journal Articles

Multi-Omics Profiling Reveals Tumor Cellular Landscape and Metabolism Remodeling during Extranodal Natural Killer/T-Cell Lymphoma (ENKTL) Metastasis and Progression

Jinhua Liang, Kai-Xin Du, Yue Li, Tong-Yao Xing, Hao-Rui Shen, Jiazhu Wu, Hua Yin, Li Wang, Jianyong Li, Xu Wei

Blood (2024) 144 (Supplement 1): 2961.

https://doi.org/10.1182/blood-2024-201455

Published: 2024

Journal Articles

YL0712-3, a Novel ATR/ATM Inhibitor, Demonstrates Anti-Tumor Activity in TP53 Mutant DLBCL through Synthetic Lethality and Degradation of Mutant p53

Li Wang, Guo Zhang, Hui Zhou, Ting Niu

Blood (2024) 144 (Supplement 1): 4165.

https://doi.org/10.1182/blood-2024-207718

Published: 2024

Journal Articles

Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Who Are Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKi): Updated Results from a Phase 2 Study

Lin Shen, Jing Bao, Lihong Shou, Ying Lu, Qi Zhu, Li Wang, Weili Zhao

Blood (2024) 144 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2024-204547

Published: 2024

NARROW

The Clinical Efficacy and Safety of Glofitamab in Chinese Relapsed or Refractory Large B-Cell Lymphoma

A Phase 2 Multicenter Study of Pegaspargase in Combination with Gemcitabine, Etoposide, Mitoxantrone Hydrochloride Liposome, and Dexamethasone (P-GEMD) for Newly Diagnosed Early Non-Upper Aero-Digestive Tract or Advanced Stage Extranodal NK/T Cell Lymphoma

Auto-HSCT Vs CAR-T Cell Therapy for Paients with Relapsed/Refractory DLBCL in Partial Remission with Deauville Score of 4 or 5 after Salvage Chemotherapy

Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

Serum Tsrna Can be Used As a Biomarker of the Activation States of T Cells for Early Detection of GvHD after Allogeneic Stem Cell Transplantation

Over-Expression of GATA3 in Large B-Cell Lymphoma Predicts Better Prognosis

Investigating Prognostic Value of Immunoglobulin Next-Generation Sequencing in B Cell Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Integration of Gene Mutations in Risk Prognostication for Watch-and-Wait Follicular Lymphoma Patients Initiating First-Line Treatment

R-Cmop and Pola-R-CMP Regimes As First-Line Treatment for Diffuse Large B-Cell Lymphoma with Cardiac Comorbidity

Targeting YTHDC1 Inhibited the Progression of Mantle Cell Lymphoma By Inhibiting the Expression of MYC Gene through m6A Modification

Practical Microenvironment Classification in Diffuse Large B-Cell Lymphoma Using Digital Pathology

The First-in-Class PTPN2/1 Inhibitor Abbv-CLS-484 Disrupts Mitochondrial Renewal and Blocks Tfrc-Mediated PINK1-Prkn-Dependent Mitophagy to Exert Anti-Tumor Activities in ALK-Positive Anaplastic Large Cell Lymphoma

Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort

A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia

Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma：a Phase 2 Multicenter Study

Multi-Omics Profiling Reveals Tumor Cellular Landscape and Metabolism Remodeling during Extranodal Natural Killer/T-Cell Lymphoma (ENKTL) Metastasis and Progression

YL0712-3, a Novel ATR/ATM Inhibitor, Demonstrates Anti-Tumor Activity in TP53 Mutant DLBCL through Synthetic Lethality and Degradation of Mutant p53

Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Who Are Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKi): Updated Results from a Phase 2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only